Lineage Cell Therapeutics to Announce Q2 2024 Financials and Business Update on August 8, 2024

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company specializing in allogeneic cell therapies for unmet medical needs, has scheduled the release of its second quarter 2024 financial and operational results for Thursday, August 8, 2024, after the U.S. financial markets close. The company's management will also host a conference call and webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on the same day to discuss these results and provide a business update.

Participants can join the conference call on August 8, 2024, by dialing (800) 715-9871 from the U.S. and Canada and requesting the "Lineage Cell Therapeutics Call." Additionally, a live webcast of the call will be accessible in the Investors section of Lineage’s website. For those unable to attend the live event, a replay of the webcast will be available on the company’s website for 30 days. A telephone replay can be accessed through August 15, 2024, by dialing (800) 770-2030 and entering the conference ID number 6024260.

Lineage Cell Therapeutics focuses on creating off-the-shelf cell therapies using its proprietary cell-based technology platform. The company designs, develops, manufactures, and tests specialized human cells that mimic the anatomical and physiological functions of naturally occurring human cells. By applying directed differentiation protocols to well-characterized, self-renewing pluripotent cell lines, Lineage generates cells specific to desired developmental lineages. These cells are transplanted into patients to replace or support missing or dysfunctional cells caused by degenerative diseases, aging, or traumatic injury, aiming to restore or enhance the patient’s functional activity.

The company has several key programs in its neuroscience-focused pipeline. OpRegen®, a retinal pigment epithelial cell therapy, is currently in Phase 2a development in collaboration with Roche and Genentech for treating geographic atrophy secondary to age-related macular degeneration. Another program, OPC1, is an oligodendrocyte progenitor cell therapy in Phase 1/2a development for spinal cord injuries. Additionally, ANP1, an auditory neuronal progenitor cell therapy, is being explored for the treatment of auditory neuropathy, while PNC1, a photoreceptor neural cell therapy, is under investigation for treating vision loss due to photoreceptor dysfunction or damage. Lastly, RND1, a novel hypoimmune induced pluripotent stem cell line, is being developed in collaboration with Eterna Therapeutics Inc.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!